We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

PVSRIPO With/Without Lomustine

This study is currently recruiting participants.
Verified November 2017 by Duke University
Sponsor:
ClinicalTrials.gov Identifier:
NCT02986178
First Posted: December 8, 2016
Last Update Posted: November 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Istari Oncology, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Duke University
December 6, 2016
December 8, 2016
November 6, 2017
June 1, 2017
May 2021   (Final data collection date for primary outcome measure)
24-month overall survival [ Time Frame: 24 months after administration of PVSRIPO ]
The percentage of participants alive at 24 months after the administration of PVSRIPO. Overall survival is calculated from the date of administration of PVSRIPO until the date of death, or the date of last follow-up if alive. Kaplan-Meier methods are used to estimate overall survival.
Same as current
Complete list of historical versions of study NCT02986178 on ClinicalTrials.gov Archive Site
Percentage of participants with grade 3, 4, or 5 treatment-related adverse events [ Time Frame: Up to 24 months; events will be assessed continuously from the time of catheter placement for PVSRIPO administration until 30 days after a participant goes off study. ]
The percentage of particpants with grade 3, 4 or 5 adverse events possibly, probably or definitely related to administration of PVSRIPO or Lomustine.
Same as current
Not Provided
Not Provided
 
PVSRIPO With/Without Lomustine
A Randomized Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) Alone or in Combination With Lomustine in Recurrent WHO Grade IV Malignant Glioma Patients
This is a randomized phase 2 study of oncolytic polio/rhinovirus recombinant (PVSRIPO) alone or in combination with the chemotherapy drug lomustine in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
This is a randomized phase 2 study of oncolytic polio/rhinovirus recombinant (PVSRIPO) alone or in combination with the chemotherapy drug lomustine in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke. The primary objective of this study is to assess the survival of subjects receiving PVSRIPO with or without a single dose of lomustine relative to the survival observed in a historical control group. The secondary objective is to assess the safety of PVSRIPO in combination with lomustine. Subjects will be randomized to receive either PVSRIPO alone, or PVSRIPO in combination with a single dose of lomustine 8 weeks after PVSRIPO infusion, to evaluate the impact of these treatment regimens on 24-month survival relative to historical controls. PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. Subjects randomized to the lomustine arm will receive a single oral dose of 110 mg/m2 lomustine 8 weeks after PVSRIPO administration. If a subject has been treated with bevacizumab in the time since PVSRIPO infusion, the lomustine dose will be dispensed as an oral therapy at 90 mg/m2 one time only 8 weeks after PVSRIPO infusion. The target accrual for the study is 62 patients, 31 patients per arm. All patients who are randomized and receive PVSRIPO treatment will be included in efficacy and safety analyses.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Malignant Glioma
  • Biological: PVSRIPO
    A single dose of an oncolytic polio/rhinovirus recombinant (PVSRIPO)
  • Drug: Lomustine
    A single oral dose of 110 mg/m2 lomustine 8 weeks after PVSRIPO administration. If a subject has been treated with bevacizumab in the time since PVSRIPO infusion, the lomustine dose will be dispensed as an oral therapy at 90 mg/m2 one time 8 weeks after PVSRIPO infusion.
    Other Name: Gleostine
  • Experimental: Polio/Rhinovirus Recombinant (PVSRIPO)
    Polio/Rhinovirus Recombinant (PVSRIPO)
    Intervention: Biological: PVSRIPO
  • Experimental: Polio/Rhinovirus Recombinant (PVSRIPO) + Lomustine
    Polio/Rhinovirus Recombinant (PVSRIPO) + Lomustine
    Interventions:
    • Biological: PVSRIPO
    • Drug: Lomustine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
62
May 2023
May 2021   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have a recurrent supratentorial WHO grade IV malignant glioma based on imaging studies with measurable disease (≥ 1 cm and ≤ 5.5 cm of contrast-enhancing tumor). Prior histopathology consistent with a World Health Organization (WHO) grade IV malignant glioma confirmed by the study pathologist.
  • Age ≥ 18 years of age at the time of entry into the study.
  • Karnofsky Performance Score (KPS) ≥ 70%.
  • Prothrombin and Partial Thromboplastin Times ≤ 1.2 x normal prior to biopsy.
  • Total bilirubin, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase ≤ 2.5 x normal prior to biopsy.
  • Neutrophil count ≥ 1000 prior to biopsy.
  • Hemoglobin ≥ 9 prior to biopsy.
  • Platelet count ≥ 125,000/µl prior to biopsy; Platelet count ≥ 100,000/µl prior to infusion.
  • Creatinine ≤ 1.2 x normal range prior to biopsy.
  • Positive serum anti-poliovirus titer prior to biopsy.
  • The patient must have received a boost immunization with trivalent inactivated IPOL™ (Sanofi-Pasteur) at least 1 week prior to administration of the study agent.
  • At the time of biopsy, prior to administration of virus, the presence of recurrent tumor must be confirmed by histopathological analysis.
  • A signed informed consent form approved by the Institutional Review Board (IRB) will be required for patient enrollment into the study. Patients must be able to read and understand the informed consent document and must sign the informed consent indicating that they are aware of the investigational nature of this study.
  • Able to undergo brain MRI with and without contrast.

Exclusion Criteria:

  • Females who are pregnant or breast-feeding. Female patients of child-bearing potential or female sexual partners (who are of child-bearing potential) of male patients must use at least one of the following methods of medically acceptable contraceptives: approved hormonal contraceptives (such as birth control pills, patches, implants or infusions), an intrauterine device (IUD), or a barrier method of contraception (such as a condom or diaphragm) used with spermicide. Because all patients are required to have a boost immunization of trivalent inactivated IPOL™, there should be no risk of transmission of a mother to her fetus after receiving intracranial PVSRIPO. As such, patients who become pregnant after receiving PVSRIPO will continue to be monitored in the same manner, i.e. per protocol, unless the assessment is contra-indicated during pregnancy. Partners who become pregnant will sign a Pregnant Partner Information Form and information regarding the pregnancy and its outcome may be collected.
  • Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons or their designate.
  • Patients with severe, active co-morbidity, defined as follow:

    • Patients with an active infection requiring treatment or having an unexplained febrile illness (Tmax > 99.5°F/37.5°C).
    • Patients with known immunosuppressive disease or known human immunodeficiency virus infection.
    • Patients with impaired cardiac function or clinically significant cardiac disease, such as congestive heart failure requiring treatment (New York Heart Association Class ≥ 2), uncontrolled hypertension or clinically significant arrhythmia; QTcF > 470 msec on electrocardiogram (ECG) if performed or congenital long QT syndrome; acute myocardial infarction or unstable angina pectoris < 3 months prior to study.
    • Patients with known lung (FEV1 < 50%) disease or uncontrolled diabetes mellitus.
    • Patients with albumin allergy.
    • Patients with gadolinium allergy.
  • Patients with a previous history of neurological complications due to poliovirus infection.
  • Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy. Guidelines for this recovery period are dependent upon the specific therapeutic agent being used.
  • Patients may not have received chemotherapy or bevacizumab ≤ 4 weeks [except for nitrosourea (6 weeks) or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide (1 week)] prior to starting the study drug unless patients have recovered from side effects of such therapy.
  • Patients may not have received immunotherapy ≤ 4 weeks prior to starting the study drug unless patients have recovered from side effects of such therapy.
  • Patients may not be less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 progressive scans at least 4 weeks apart or histopathologic confirmation.
  • Patients who have not completed all standard of care treatments, including surgical procedure and radiation therapy (at least 59Gy).

    • If the MGMT (O(6)-methylguanine-DNA methyltransferase) promoter in their tumor is known to be unmethylated, patients are not mandated to have received chemotherapy prior to participating in this trial.
    • If the MGMT promoter in their tumor is known to be methylated or the MGMT promoter methylation status is unknown at time of screening, patients must have received at least one chemotherapy regimen prior to participating in this trial.
  • Patients with neoplastic lesions in the brainstem, cerebellum, or spinal cord, radiological evidence of active (growing) multifocal disease, subependymal or leptomeningeal disease.
  • Patients with undetectable anti-tetanus toxoid IgG (Immunoglobulin G).
  • Patients with known history of agammaglobulinemia.
  • Patients on greater than 4 mg per day of dexamethasone within the 2 weeks prior to admission for PVSRIPO infusion.
  • Patients with worsening steroid myopathy (history of gradual progression of bilateral proximal muscle weakness, and atrophy of proximal muscle groups).
  • Patients with prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin.
  • Patients with a known history of hypersensitivity to lomustine, dacarbazine, or any components of lomustine.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: David Ashley, MBBS, FRACP, PhD 919-684-5301 dukebrain1@dm.duke.edu
Contact: Stevie Threatt 919-684-5301 dukebrain1@dm.duke.edu
United States
 
 
NCT02986178
Pro00077024
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Duke University
Duke University
  • Istari Oncology, Inc.
  • National Cancer Institute (NCI)
Principal Investigator: David Ashley, MBBS, FRACP, PhD Duke University
Study Director: Darell Bigner, MD, PhD Istari Oncology, Inc.
Duke University
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP